Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

por Adamo, Vincenzo, Ricciardi, Giuseppina Rosaria Rita, Giuffrida, Dario, Scandurra, Giuseppa, Russo, Antonio, Blasi, Livio, Spadaro, Pietro, Iacono, Carmelo, Soto Parra, Hector J., Savarino, Antonino, Ferraú, Francesco, Zerilli, Filippo, Verderame, Francesco, Butera, Alfredo, Santangelo, Carlo, Franchina, Veronica, Caruso, Michele
Publicado 2019